Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2022, specifically reporting on the vesting of awards under the 2017 Performance Share Plan (PSP) granted in 2019. The performance period for these awards ran from January 1, 2019, to December 31, 2021. The filing details the vesting outcomes for Persons Discharging Managerial Responsibilities (PDMRs) and their Persons Closely Associated (PCAs), along with subsequent share sales to meet tax liabilities.
Key Financial Metrics and Performance Outcomes
The filing provides specific performance metrics used to determine vesting levels for the 2019 PSP awards. The overall vesting outcome for the 2019 award was 58% of the maximum potential, with 42% lapsed.
| Performance Measure | Outcome | Vesting Level | Portion of Award |
|---|---|---|---|
| Adjusted Free Cash Flow | £14.53bn achieved (Target: £13.20bn) | 100% of maximum | 33.33% |
| Total Shareholder Return | Ranked 10th (Below threshold) | 0% of maximum | 0% |
| R&D New Products | £11.12bn achieved (75% target: £11.14bn) | 74% of maximum | 24.66% |
On the vesting date of February 16, 2022, the closing price for GSK Ordinary Shares was £15.76, and American Depositary Shares (ADSs) were $43.39.
Material Changes and Transactions
The filing documents specific transactions executed on February 16, 2022, for various executives. These transactions consist of the vesting of shares/ADSs at a price of £0.00 or $0.00, followed by sales of a portion of those shares to cover tax liabilities.
- Ms E Walmsley (CEO): Vested 274,480 Ordinary Shares.
- Mr I Mackay (CFO): Vested 152,815 Ordinary Shares.
- Dr H Barron (CSO): Vested 146,831 ADSs; sold 79,172 ADSs at $43.3404 to meet tax liabilities.
- Mr R Connor (President, Vaccines): Vested 119,780 Ordinary Shares; sold 56,297 shares at £15.8269 to meet tax liabilities.
- Ms D Conrad (Chief People Officer): Received a cash payment of £126,710.48 (less tax) in lieu of 8,006 notional shares.
- Other Executives: Similar vesting and tax sale transactions were recorded for Mr J Ford, Ms S Jackson, Mr D Jackson, Mr B McNamara, Mr L Miels, Ms S Ramakrishnan, Mr D Redfern, Mr R Simard, Mr P Thomson, Ms D Waterhouse, and Ms V Whyte.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future strategy, or specific risk factors beyond the standard disclosure of performance conditions. It notes that adjustments to the original target and vesting schedule were communicated in the 2020 Annual Report and will be detailed in the 2021 Annual Report. The vested shares for Executive Directors are subject to an additional two-year vesting period.
Key Facts for Investor Verification
- Performance Shortfall: The company failed to meet the Total Shareholder Return threshold, resulting in 0% vesting for that third of the award.
- Near Miss on R&D: New Product sales (£11.12bn) fell slightly short of the £11.14bn required for 75% vesting, resulting in a 74% payout for that metric.
- Strong Cash Flow: Adjusted Free Cash Flow significantly exceeded the target, securing 100% vesting for that portion.
- Executive Retention: Vested shares for Executive Directors are subject to a further two-year holding period.
- Tax Sales: A significant portion of vested shares for many executives was immediately sold to cover tax liabilities, indicating standard tax withholding practices rather than discretionary selling.